Recombinant multi-species UBA2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine UBA2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Posttranslational modification of proteins by the addition of the small protein SUMO (see SUMO1; MIM 601912), or sumoylation, regulates protein structure and intracellular localization. SAE1 (MIM 613294) and UBA2 form a heterodimer that functions as a SUMO-activating enzyme for the sumoylation of proteins (Okuma et al., 1999 [PubMed 9920803]).[supplied by OMIM, Mar 2010]
The Alternative Names of target: ACCES,ARX,Anthracycline-associated resistance ARX,Arx,HRIHFB2115,SAE2,SUMO-activating enzyme subunit 2,Sae2,UBA1,UBA2,Uba2,Ubiquitin-like 1-activating enzyme E1B,Ubiquitin-like modifier-activating enzyme 2,Ubl1a2,Uble1b

Target products collectionGo to UBA2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP3215-Ag-1/ GM-Tg-hg-IP3215-Ag-2 Human UBA2 protein Human
GM-Tg-rg-IP3215-Ag-1/ GM-Tg-rg-IP3215-Ag-2 Rat UBA2 protein Rat
GM-Tg-mg-IP3215-Ag-1/ GM-Tg-mg-IP3215-Ag-2 Mouse UBA2 protein Mouse
GM-Tg-cynog-IP3215-Ag-1/ GM-Tg-cynog-IP3215-Ag-2 Cynomolgus/Rhesus macaque UBA2 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP3215-Ag-1/ GM-Tg-felg-IP3215-Ag-2 Feline UBA2 protein Feline
GM-Tg-cang-IP3215-Ag-1/ GM-Tg-cang-IP3215-Ag-2 Canine UBA2 protein Canine
GM-Tg-bovg-IP3215-Ag-1/ GM-Tg-bovg-IP3215-Ag-2 Bovine UBA2 protein Bovine
GM-Tg-equg-IP3215-Ag-1/ GM-Tg-equg-IP3215-Ag-2 Equine UBA2 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP3215-Ag-1/ GM-Tg-hg-IP3215-Ag-2; GM-Tg-rg-IP3215-Ag-1/ GM-Tg-rg-IP3215-Ag-2;
GM-Tg-mg-IP3215-Ag-1/ GM-Tg-mg-IP3215-Ag-2; GM-Tg-cynog-IP3215-Ag-1/ GM-Tg-cynog-IP3215-Ag-2;
GM-Tg-felg-IP3215-Ag-1/ GM-Tg-felg-IP3215-Ag-2; GM-Tg-cang-IP3215-Ag-1/ GM-Tg-cang-IP3215-Ag-2;
GM-Tg-bovg-IP3215-Ag-1/ GM-Tg-bovg-IP3215-Ag-2; GM-Tg-equg-IP3215-Ag-1/ GM-Tg-equg-IP3215-Ag-2
Products Name UBA2 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name UBA2
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine UBA2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.